Respiratory Failure Due to Idiopathic Pneumonia Syndrome in a Pediatric Patient After Recipient-derived Allogeneic Chimeric Antigen Receptor T-Cell Therapy.
J Pediatr Hematol Oncol
; 45(6): e775-e780, 2023 08 01.
Article
em En
| MEDLINE
| ID: mdl-37314946
ABSTRACT
Idiopathic pneumonia syndrome (IPS) is a life-threatening complication of hematopoietic cell transplantation, but it is not clearly described following chimeric antigen receptor (CAR) T-cell therapy. We describe a child who developed IPS after receiving tisagenlecleucel for post-hematopoietic cell transplantation relapsed acute lymphoblastic leukemia and had a remarkable improvement after treatment with corticosteroids and etanercept. We discuss the implications of cytokine signaling in IPS and immunologic considerations of allogeneic CAR T cells. We anticipate that the incidence of IPS and other allogeneic phenomena will be observed more often as allogeneic CAR T cells are employed in more varied settings with more mismatched donors.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pneumonia
/
Insuficiência Respiratória
/
Transplante de Células-Tronco Hematopoéticas
/
Receptores de Antígenos Quiméricos
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article